Evonetix is a synthetic biology company bringing semiconductor technology to DNA synthesis.

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale.

Evonetix was founded in 2015. The company is headquartered in Cambridge, United Kingdom.

Evonetix designed novel semiconductor technology capable of synthesising thousands of independent sequences across the surface of a single chip, re-engineered phosphoramidite chemistry to enable thermal control of the synthesis cycle, developed new ways to assemble DNA into genes and established novel approaches to enzymatic DNA synthesis.

Evonetix’s proprietary synthesis process utilizes a novel silicon chip, to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or ‘pixels’, and their assembly into highly accurate long DNA on the chip surface through the company’s patented Binary Assembly process.

Evonetix's Bioengineering Platform will enable independent synthesis of thousands of distinct DNA strands per run, allowing 100’s of kilobases of DNA to be assembled into genes and providing DNA pools for CRISPR Screening, Antibody Discovery, Target Enrichment, Saturation Mutagenesis and more.

Evonetix is backed by Draper Esprit, DCVC, Foresite Capital, the Morningside group, Providence, Molten Ventures, Cambridge Consultants, Civilization Ventures, and others. The company completed a $24M (£20M) financing on Feb 07, 2023, extending its total series B to over $54M (£43M). The additional investment brings Evontex's total funding to $70M to date.